Join us for an exciting new event on the latest research on the full patient pathway across the key urological cancers, developing an understanding of the role played by different members of the MDT in providing evidence-based care and the impact cancer has on patients including survivorship and palliative support.
Building on last year's Urology Section Cancer Day, this event will feature internationally renowned speakers from across the urology MDT including urologists, radiologists, oncologists, pathologists and specialist nurses. In doing so, we will provide a unique holistic insight into the management of patients with urological cancers relevant to those involved in caring for these patients and those studying for the FRCS(Urol) exam.
The day will include updates on the management of penile cancer, metastatic prostate cancer, non-muscle invasive bladder cancer (NMIBC) and localised kidney cancer. We will also gain an insight on how survivorship from various urological cancers has changed over time including for young men treated for testis cancer and the role of patient charities.
°Õ³ó±ðÌý will also be presented and awarded at the meeting.ÌýÌýto make your submission.Ìý
ÌýParticipants will learn about:Ìý
- Management of penile cancer
- Role of patient charities
- Management of NMIBC
- Management of metastatic prostate cancer
- The surgical treatment of localized kidney cancer
- The impact of treatment of testis cancer
--------------
Interested in applying for the
Deadline: Saturday 12 October 2024
Open to:ÌýAll Urological Trainees and SAS Doctors working in Urology
Prizes:
1st: £600 towards the Urological EducationÌýÌý
2nd: £300 towards the Urological Education
3rd: £150 towards the Urological Education
Follow us on:Ìý
Ìý
Ìý
Ìý
Ìý
Ìý
We would like to thank our sponsors Accord, Astellas, Bayer, iMEDicare, Ipsen, Medac PharmaÌýand our exhibitor Photocure for their support and funding of this event. We would also like to thank Prostate Cancer UK who have provided funding towards this event via an education bursary. Please note that the main scientific programme and content has not been influenced in any way by the organisations listed above.